Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares Repurchased
Ratios

Ligand Pharmaceuticals (LGND) Leases (2019 - 2025)

Ligand Pharmaceuticals' Leases history spans 7 years, with the latest figure at $5.2 million for Q4 2025.

  • For Q4 2025, Leases rose 86.26% year-over-year to $5.2 million; the TTM value through Dec 2025 reached $5.2 million, up 86.26%, while the annual FY2025 figure was $5.2 million, 86.26% up from the prior year.
  • Leases for Q4 2025 was $5.2 million at Ligand Pharmaceuticals, down from $7.6 million in the prior quarter.
  • Across five years, Leases topped out at $32.1 million in Q3 2022 and bottomed at $800000.0 in Q1 2025.
  • The 5-year median for Leases is $7.3 million (2024), against an average of $8.9 million.
  • The largest annual shift saw Leases surged 203.37% in 2021 before it plummeted 86.73% in 2025.
  • A 5-year view of Leases shows it stood at $3.2 million in 2021, then increased by 24.61% to $4.0 million in 2022, then fell by 15.18% to $3.4 million in 2023, then dropped by 18.48% to $2.8 million in 2024, then surged by 86.26% to $5.2 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Leases are $5.2 million (Q4 2025), $7.6 million (Q3 2025), and $8.0 million (Q2 2025).